Virpax Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Berwyn, pa.--(business wire)-- #pharma--virpax® pharmaceuticals, inc. (“virpax” or the “company”) (nasdaq: vrpx), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (cns) disorders and anti-viral indications, today announced it will pursue an otc intranasal medical device consumer regulatory pathway for anqlar™, the company's product candidate being developed as a prophylactic antiviral barrier against influenza and sars

Berwyn, pa.--(business wire)-- #pharma--virpax® pharmaceuticals, inc. (“virpax” or the “company”) (nasdaq: vrpx), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (cns) disorders and anti-viral indications, today announced that it will pursue a direct to otc regulatory pathway for epoladerm™, the company's product candidate to treat pain associated with osteoarthritis. the direct to otc, non-prescription regulatory pat

Berwyn, pa.--(business wire)-- #pharma--virpax® pharmaceuticals, inc. (“virpax” or the “company”) (nasdaq: vrpx), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (cns) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement (crada) with the u.s. army institute of surgical research (usaisr) to evaluate virpax's probudur™, an injectable long-acting

Berwyn, pa.--(business wire)-- #earnings--virpax® pharmaceuticals, inc. (“virpax” or the “company”) (nasdaq:vrpx), today announced its financial results for the twelve months ended december 31, 2021, and other recent developments. “in the fourth quarter of 2021 and into the beginning of 2022, we have continued to make progress on all of the product candidates in our pipeline,” stated anthony p. mack, chairman and chief executive officer of virpax. “we recently announced that we have selected a leading clin

Berwyn, pa.--(business wire)-- #pharma--virpax® pharmaceuticals, inc. (“virpax” or the “company”) (nasdaq: vrpx), a company specializing in developing non-addictive products for pain management post-traumatic stress disorder, central nervous system disorders and anti-viral indications, completed all fda required pre-clinical studies for epoladerm™, virpax's investigational pre-filled topical spray analgesic product to manage chronic pain associated with osteoarthritis (oa) of the knee. the key investigat

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the worldwide rights for development and commercialization. Virpax has completed in-vitro, ex-vivo (human mucosal cells), and in-vivo (rats).

The stock price of Virpax Pharmaceuticals Inc (NASDAQ: VRPX) increased by over 38% during intraday trading today. This is why it happened.

4 Reddit penny stocks to watch right now. The post 4 Reddit Penny Stocks To Buy For Under $5 As Trump Stocks Jump appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of an underwritten public offering of 6,670,000 shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $40,020,000, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 45-day option to

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of an underwritten public offering of 6,670,000 shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $40,020,000 million, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 45-day o

Virpax has exclusive worldwide rights to non-opioid, non-addictive analgesic delivery systems. The company's pipeline has candidates eligible for abbreviated regulatory pathway as well as an OTC.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

On Wednesday, Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) shares soared more than 97% before pulling back later for a net intraday gain of 43%. The stock is now up more than 470% from its Monday close following Tuesday's events.